Valuation: Forte Biosciences, Inc.

Market Cap 897M 785M 723M 669M 1.27B 85.6B 1.29B 8.66B 3.4B 42.04B 3.37B 3.29B 146B P/E 2026 *
-8.94x
P/E 2027 * -8.63x
Enterprise Value 897M 785M 723M 669M 1.27B 85.6B 1.29B 8.66B 3.4B 42.04B 3.37B 3.29B 146B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.86%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Forte Biosciences, Inc.

1 day+78.33%
1 week+75.43%
Current month+72.71%
1 month+115.88%
3 months+8.26%
6 months+53.69%
Current year+34.58%
1 week 19.95
Extreme 19.95
37.58
1 month 16.6
Extreme 16.6
37.58
Current year 15.51
Extreme 15.51
37.58
1 year 9.1
Extreme 9.1
37.58
3 years 4.11
Extreme 4.11
37.58
5 years 4.11
Extreme 4.11
921.25
10 years 4.11
Extreme 4.11
1,349.75
Manager TitleAgeSince
Chief Executive Officer 55 01/01/2018
Director of Finance/CFO 59 01/03/2020
Chief Operating Officer - 01/10/2020
Director TitleAgeSince
Chairman 55 -
Director/Board Member 58 01/06/2020
Director/Board Member 79 16/03/2022
Date Insider Type Main position Quantity % Market Cap.
07-01Fiscal year

Chief Financial Officer

884 0.0043%
07-01Fiscal year

Chief Executive Officer

2,598 0.0127%
06-16Free

Chief Financial Officer

22,000 0.1074%
Change 5-day change 1-year change 3-year change Capi.($)
+78.33%+75.43%+194.07%+45.35% 897M
-0.20%-4.26%+63.86%+126.22% 56.98B
+4.91%-0.19%+73.70%+92.14% 53.58B
+1.48%+5.97%+22.59%+495.47% 25.63B
-0.59%-4.68%-16.82%-12.99% 23.51B
+2.43%+1.06%+47.70%-0.11% 19.43B
-0.95%+2.54%+37.40%-25.01% 18.12B
-6.84%+2.18%+203.03%+348.11% 16.46B
+8.74%+3.51%+53.81% - 14.13B
+1.76%+2.24%+29.57%+195.70% 14.35B
Average +8.91%+8.32%+70.89%+140.54% 24.31B
Weighted average by Cap. +1.70%-0.03%+57.90%+142.58%

Financials

2026 *2027 *
Net sales - -
Net income -95.54M -83.58M -77.07M -71.31M -135M -9.12B -138M -923M -362M -4.48B -359M -351M -15.51B -130M -114M -105M -97.36M -185M -12.45B -188M -1.26B -494M -6.11B -490M -479M -21.18B
Net Debt - -
Logo Forte Biosciences, Inc.
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is an anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. It is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The Company's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.
Employees
22
Date Price Change Volume
09/07/26 US$36.70 +78.33% 4,866,491
08/07/26 US$20.58 -7.51% 590,078
07/07/26 US$22.25 +9.02% 500,708
06/07/26 US$20.41 -2.44% 242,497
02/07/26 US$20.92 -1.88% 401,572
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
36.70USD
Average target price
63.75USD
Spread / Average Target
+73.71%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FBRX Stock